Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | FRK | P42685 | 2/20 | 0.41 |
| ▸ | BLK | P51451 | 2/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.41 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.41 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957417 | 0.92 | KDR (0.56) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL5524330 | 0.91 | KDR (0.55) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL187362 | 0.90 | KDR (0.53) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6054218 | 0.88 | KDR (0.51) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6054204 | 0.88 | KDR (0.56) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL3890568 | 0.87 | KDR (0.55) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL3960750 | 0.86 | KDR (0.44) | KDRNPC1RAB9ASMN1; SMN2FLT1 | |
| SCHEMBL3890961 | 0.86 | KDR (0.56) | KDRNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4765047 | 0.85 | KDR (0.44) | KDRRAB9AFLT1MAP4K4EGFR | |
| SCHEMBL3892504 | 0.85 | KDR (0.53) | KDRNPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100074909-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2010-03-25 | — | — | US | claimed |
| JP-4338974-B2 | — | — | 2009-10-07 | — | — | JP | claimed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | claimed |
| US-7105682-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2006-09-12 | — | — | US | claimed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| JP-2004527499-A | — | — | 2004-09-09 | — | — | JP | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-3170824-B1 | A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR | AMGEN INC (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3330292-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | Amgen, Inc (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9988457-B2 | Human C-FMS antigen binding proteins | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2188313-B1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2005017107-A2 | SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR | AMGEN INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885NPC1 593/4885RAB9A 3057/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885NPC1 782/4885RAB9A 2278/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | KDR 13/4885NPC1 782/4885RAB9A 2278/4885 |
| US-20100074909-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | KDR 2043/4885NPC1 593/4885RAB9A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.